Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The identification of a new role for LEKTI in the skin: The use of protein 'bait' arrays to detect defective trafficking of dermcidin in the skin of patients with Netherton syndrome.

Bennett K, Heywood W, Di WL, Harper J, Clayman GL, Jayakumar A, Callard R, Mills K.

J Proteomics. 2012 Jul 16;75(13):3925-37. doi: 10.1016/j.jprot.2012.04.045. Epub 2012 May 12.

PMID:
22588119
2.

Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.

Fortugno P, Bresciani A, Paolini C, Pazzagli C, El Hachem M, D'Alessio M, Zambruno G.

J Invest Dermatol. 2011 Nov;131(11):2223-32. doi: 10.1038/jid.2011.174. Epub 2011 Jun 23.

3.

New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI.

Bennett K, Callard R, Heywood W, Harper J, Jayakumar A, Clayman GL, Di WL, Mills K.

J Proteome Res. 2010 Aug 6;9(8):4289-94. doi: 10.1021/pr1003467.

PMID:
20533828
4.

Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.

Meyer-Hoffert U, Wu Z, Schröder JM.

PLoS One. 2009;4(2):e4372. doi: 10.1371/journal.pone.0004372. Epub 2009 Feb 3.

5.

SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.

Wang S, Olt S, Schoefmann N, Stuetz A, Winiski A, Wolff-Winiski B.

Exp Dermatol. 2014 Jul;23(7):524-6. doi: 10.1111/exd.12451.

PMID:
24848304
6.

LEKTI domain 15 is a functional Kazal-type proteinase inhibitor.

Vitzithum K, Lauber T, Kreutzmann P, Schulz A, Sommerhoff CP, Rösch P, Marx UC.

Protein Expr Purif. 2008 Jan;57(1):45-56. Epub 2007 Sep 5.

PMID:
17936012
7.

A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.

Borgoño CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, Diamandis EP.

J Biol Chem. 2007 Feb 9;282(6):3640-52. Epub 2006 Dec 11.

8.

Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).

Schechter NM, Choi EJ, Wang ZM, Hanakawa Y, Stanley JR, Kang Y, Clayman GL, Jayakumar A.

Biol Chem. 2005 Nov;386(11):1173-84.

PMID:
16307483
9.

LEKTI-1 in sickness and in health.

Roelandt T, Thys B, Heughebaert C, De Vroede A, De Paepe K, Roseeuw D, Rombaut B, Hachem JP.

Int J Cosmet Sci. 2009 Aug;31(4):247-54. doi: 10.1111/j.1468-2494.2009.00516.x. Epub 2009 May 13. Review.

10.

When activity requires breaking up: LEKTI proteolytic activation cascade for specific proteinase inhibition.

Furio L, Hovnanian A.

J Invest Dermatol. 2011 Nov;131(11):2169-73. doi: 10.1038/jid.2011.295.

11.

Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome.

Sales KU, Masedunskas A, Bey AL, Rasmussen AL, Weigert R, List K, Szabo R, Overbeek PA, Bugge TH.

Nat Genet. 2010 Aug;42(8):676-83. doi: 10.1038/ng.629. Epub 2010 Jul 25.

12.

LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.

Deraison C, Bonnart C, Lopez F, Besson C, Robinson R, Jayakumar A, Wagberg F, Brattsand M, Hachem JP, Leonardsson G, Hovnanian A.

Mol Biol Cell. 2007 Sep;18(9):3607-19. Epub 2007 Jun 27.

13.

Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis.

Mitsudo K, Jayakumar A, Henderson Y, Frederick MJ, Kang Y, Wang M, El-Naggar AK, Clayman GL.

Biochemistry. 2003 Apr 8;42(13):3874-81.

PMID:
12667078
14.

hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6.

Egelrud T, Brattsand M, Kreutzmann P, Walden M, Vitzithum K, Marx UC, Forssmann WG, Mägert HJ.

Br J Dermatol. 2005 Dec;153(6):1200-3.

PMID:
16307658
15.

Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients.

Komatsu N, Saijoh K, Jayakumar A, Clayman GL, Tohyama M, Suga Y, Mizuno Y, Tsukamoto K, Taniuchi K, Takehara K, Diamandis EP.

J Invest Dermatol. 2008 May;128(5):1148-59. Epub 2007 Nov 8.

16.

LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.

Ishida-Yamamoto A, Deraison C, Bonnart C, Bitoun E, Robinson R, O'Brien TJ, Wakamatsu K, Ohtsubo S, Takahashi H, Hashimoto Y, Dopping-Hepenstal PJ, McGrath JA, Iizuka H, Richard G, Hovnanian A.

J Invest Dermatol. 2005 Feb;124(2):360-6.

17.

The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.

Fortugno P, Furio L, Teson M, Berretti M, El Hachem M, Zambruno G, Hovnanian A, D'Alessio M.

Hum Mol Genet. 2012 Oct 1;21(19):4187-200. doi: 10.1093/hmg/dds243. Epub 2012 Jun 23.

PMID:
22730493
18.

LEKTI: a multidomain serine proteinase inhibitor with pathophysiological relevance.

Mägert HJ, Kreutzmann P, Ständker L, Walden M, Drögemüller K, Forssmann WG.

Int J Biochem Cell Biol. 2002 Jun;34(6):573-6. Review.

PMID:
11943586
19.

Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides.

Komatsu N, Takata M, Otsuki N, Ohka R, Amano O, Takehara K, Saijoh K.

J Invest Dermatol. 2002 Mar;118(3):436-43.

20.

SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases.

Raghunath M, Tontsidou L, Oji V, Aufenvenne K, Schürmeyer-Horst F, Jayakumar A, Ständer H, Smolle J, Clayman GL, Traupe H.

J Invest Dermatol. 2004 Sep;123(3):474-83.

Supplemental Content

Support Center